Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection. Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates, meaning that infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Ebola hemorrhagic fever has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine for Ebola virus infection.
Several research groups have developed experimental vaccine approaches that protect nonhuman primates from Ebola virus and the closely related Marburg virus. These approaches include vaccines based on DNA, recombinant adenovirus, virus-like particles, and human parainfluenza virus 3. But how these vaccine candidates confer protection is an area that is still being explored: Do they activate immune cells to kill the invading virus? Or do they elicit antibodies that block infection?
In this study, scientists at NIH's National Institute of Allergy and Infectious Diseases and OHSU's Vaccine & Gene Therapy Institute built on earlier work with an experimental vaccine composed of an attenuated vesicular stomatitis virus carrying a gene that codes for an Ebola virus protein. They observed how cynomolgus macaques responded to a challenge of Ebola virus before and during treatment with the vaccine and in conjunction with depleted levels of immune cells. Their results showed that important immune cells—CD4+ T cells and CD8+ T cells—had a minimal role in providing protection, while antibodies induced by the vaccine appeared to be critical to protecting the animals.
The scientists say this finding will help improve future Ebola virus vaccine development. They plan to focus their studies on what level of antibody production is needed to establish protection from Ebola virus infection in humans
WHO: Heinz Feldmann, M.D., Ph.D., chief of the Laboratory of Virology at NIAID's Rocky Mountain Laboratories. Dr. Feldmann is an expert on viral hemorrhagic fevers and emerging viruses.
ARTICLE: A Marzi et al. Antibodies are necessary for rVSV/ZEBOV-GP mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1209591110 (2013).
NIH/National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
A new study suggests these giant prehistoric mammals were not taken down by human hunters alone
Ankle-deep mayflies covered a Mississippi River bridge connecting Iowa to Illinois
NPR's Melissa Block speaks with John H. Richardson about his recent Esquire piece, "When the End of Human Civilization Is Your Day Job."
Amazonian wilderness buzzed with human activity until 500 years ago, when Europeans turned up with weapons and diseases, says radical rethink of rainforest history
The two permits issued Wednesday clear the way for oil drilling in Chukchi Sea, but with some conditions and limits
Iraq's fabled marshes are seeing some of the lowest water levels since Saddam Hussein drained them in the 1990s
"Climate change is not science fiction"
NPR's Melissa Block speaks to Mike Halpert, deputy director of the National Oceanic and Atmospheric Administration's Climate Prediction Center, about a strengthening El Nino season.
Researchers say the Arctic is highly sensitive to changes in summer temperatures as ice rebound continued through 2014.
Growing emissions from the burning of fossil fuels are threatening the effectiveness of radiocarbon dating say scientists.